- Home
- OMER vs NXP Comparison
OMER vs NXP Comparison
Compare OMER & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMER | NXP |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.6M | 890.4M |
| IPO Year | 2008 | 1995 |
Fundamental Metrics
Financial Performance| Metric | OMER | NXP |
|---|---|---|
| Price | $17.33 | $14.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $32.50 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 138.7K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.15 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $29,868,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $233.22 | N/A |
| P/E Ratio | $22.49 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.94 | $13.89 |
| 52 Week High | $18.14 | $14.65 |
Technical Indicators
Market Signals| Indicator | OMER | NXP |
|---|---|---|
| Relative Strength Index (RSI) | 83.27 | 53.07 |
| Support Level | $9.12 | $14.23 |
| Resistance Level | $17.65 | $14.33 |
| Average True Range (ATR) | 0.75 | 0.10 |
| MACD | 0.52 | 0.01 |
| Stochastic Oscillator | 87.76 | 73.51 |
Price Performance
Historical ComparisonAbout OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund has single operating segment.